The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors
Completed · Not applicable · Has a placebo group
Conditions studied: Fatigue
In brief
The purpose of this randomized-controlled, crossover pilot trial is to evaluate the feasibility, acceptability and effects of a non-deceptive (open-label) administration of placebo pills for treating cancer related fatigue (CRF). If significant effects are found, the investigators will later determine if the presence of a COMT Val18Met genotype variant predicts placebo responses.
Key facts
- Study ID
- NCT02522988
- Run by
- University of Alabama at Birmingham
- People needed
- 74
- Starts
- 2015-06-01
- Expected to finish
- 2021-08-01
- Last updated by the study team
- 2021-09-24
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of Stage II - IV cancer;
- Completed primary treatment 6months to 10 years;
- Report ≥4 (moderate fatigue) on a 0-10 fatigue severity rating scale;
- Agree not to change any medications or treatments during the study;
- Willingness to make 4 clinical site visits over the course of the 49-day study.
You may not qualify if…
- Stage 1 cancer;
- Uncontrolled diabetes;
- Uncontrolled COPD;
- Uncontrolled ischemic heart disease;
- Uncontrolled liver/kidney diseases;
- Uncontrolled autoimmune diseases;
- Uncontrolled psychiatric or cognitive diseases.
Where it is running
- UAB Comprehensive Cancer Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.